Cardiovascular Risk Associated with Acarbose versus Metformin as the First-line Treatment in Patients with Type 2 Diabetes: a Nationwide Cohort Study.

Conclusion: Our data do not support that acarbose has a cardio-protective effect similar to metformin as a first-line anti-diabetic agent. PMID: 25555040 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25555040?dopt=Abstract

Source: Diabetes Metab - January 2, 2015 Category: Endocrinology Authors: Chang C, Chang Y, Lin J, Chen S, Chuang L, Lai M Tags: J Clin Endocrinol Metab Source Type: research